Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 155

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 155
---
 On March 31, 2025, NewGenIvf terminated the term sheet for the EWIHL Proposed
Transaction as EWIHL had failed to produce certain draft audited financials, which were specifically required in the term sheet.

On February 28, 2025, NewGenIvf
completed its acquisition of the MicroSort technology from Genetics & IVF Institute, Inc. (“GIVF”). Pursuant to a Purchase
Agreement dated January 21, 2025 between NewGenIvf and GIVF (“Purchase Agreement”), NewGenIvf purchased all of the Assets
(as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort technology (as
described below from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Class A Ordinary Shares (equivalent
to 2,500 Class A Ordinary Shares post Third Reverse Stock Split) (“MicroSort Acquisition”).

White Lion Transaction

On November 21, 2024, the
Company entered into a Common Shares Purchase Agreement (the “White Lion Purchase Agreement”) with White Lion Capital, LLC
(“White Lion”) and a related Registration Rights Agreement (the “RRA”). Pursuant to the White Lion Purchase Agreement,
the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars
($100,000,000) in aggregate gross purchase price of newly issued Class A Ordinary Shares, with an automatic increase to Three Hundred
Million Dollars ($300,000,000) upon any substantial M&A or Material Transaction (as defined in the White Lion Purchase Agreement)
and a further option to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and Fifty Million Dollars ($250,000,000)
has been issued and sold to White Lion under the White Lion Purchase Agreement, subject to certain limitations and conditions set forth
in the White Lion Purchase Agreement.

Subject to the satisfaction
of certain customary conditions including, without limitation, the effectiveness of the Registration Statement registering the resale
of the shares issuable pursuant to the White Lion Purchase Agreement, the Company’s right to sell shares to White Lion commenced
on the date of the execution of White Lion Purchase Agreement and extends until (i) 36 months from the date of execution of the White
Lion Purchase Agreement, or (ii) at the Company’s option,